We are live on ! Find out more
ARMO

ARMO BioSciences, Inc. Common Stock
ARMO

Delisted

ARMO was delisted on the 21st of June, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in ARMO BioSciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 65 → 0 (-65)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $509M → $0 (-$509M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 63

Holders
–
Holders Change
-65
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
63
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$154M
2
AI
Alphabet Inc
California
-$45.4M
3
ACA
Avoro Capital Advisors
New York
-$45.2M
4
BlackRock
BlackRock
New York
-$30.8M
5
HH
HSG Holding
Hong Kong
-$30.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
– -$154M -4,118,903 Closed
AI
2
Alphabet Inc
California
– -$45.4M -1,214,700 Closed
ACA
3
Avoro Capital Advisors
New York
– -$45.2M -1,207,500 Closed
BlackRock
4
BlackRock
New York
– -$30.8M -822,167 Closed
HH
5
HSG Holding
Hong Kong
– -$30.3M -809,800 Closed
Jennison Associates
6
Jennison Associates
New York
– -$18.4M -493,061 Closed
RI
7
RTW Investments
New York
– -$14M -413,892 Closed
JP Morgan Chase
8
JP Morgan Chase
New York
– -$12.4M -332,548 Closed
CCP
9
Clough Capital Partners
Massachusetts
– -$12M -328,351 Closed
EA
10
Emerald Advisers
Pennsylvania
– -$11.4M -304,330 Closed
FM
11
Frazier Management
Washington
– -$11.2M -300,000 Closed
RG
12
Redmile Group
California
– -$11.2M -298,800 Closed
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
– -$10.4M -277,339 Closed
Wells Fargo
14
Wells Fargo
California
– -$10.1M -270,387 Closed
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$9.73M -260,185 Closed
BM
16
Bridger Management
New York
– -$8.68M -232,115 Closed
DM
17
Deerfield Management
New York
– -$7.05M -188,525 Closed
Franklin Resources
18
Franklin Resources
California
– -$6.55M -175,000 Closed
Millennium Management
19
Millennium Management
New York
– -$5.42M -144,821 Closed
UBS AM
20
UBS AM
Illinois
– -$4.59M -122,643 Closed
Vanguard Group
21
Vanguard Group
Pennsylvania
– -$4M -106,883 Closed
State of New Jersey Common Pension Fund D
22
State of New Jersey Common Pension Fund D
New Jersey
– -$3.74M -100,000 Closed
State Street
23
State Street
Massachusetts
– -$3.46M -92,440 Closed
PC
24
PointState Capital
New York
– -$3.04M -81,400 Closed
ACP
25
Acuta Capital Partners
California
– -$2.99M -80,000 Closed
1
2 3

ARMO Hedge Fund Activity: Q2 2018 in Review

0 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ARMO BioSciences, Inc. Common Stock (ARMO) for Q2 2018, worth a combined $0 — down 100% from $509M a quarter earlier.

Sellers outnumbered buyers: 63 funds closed out of ARMO and 0 opened new positions — a net loss of 63 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $154M sold.

  • 0 institutional investors held ARMO BioSciences, Inc. Common Stock (ARMO) as of Q2 2018, down from 65 in Q1 2018.
  • Funds reported $0 of ARMO BioSciences, Inc. Common Stock stock for Q2 2018, down 100% quarter-over-quarter.
  • 0 funds opened new ARMO BioSciences, Inc. Common Stock positions in Q2 2018 and 63 closed out, a net change of -63 holders.
  • The largest ARMO BioSciences, Inc. Common Stock seller in Q2 2018 was OrbiMed, an estimated $154M sold.

Based on aggregated 13F filings for Q2 2018.